share_log

D: Filing D

SEC announcement ·  Apr 26 04:08
Summary by Futu AI
NeuroSense Therapeutics Ltd., a biotechnology company incorporated in Israel, has successfully completed an exempt offering of securities, raising a total of $4,470,000 USD as reported in a new Form D notice filed with the U.S. Securities and Exchange Commission (SEC). The offering, which included options, warrants, or other rights to acquire securities, was conducted under Rule 506(b) of the Securities Act. The date of the first sale was April 15, 2024, and the company intends the offering to last more than one year. NeuroSense Therapeutics has declined to disclose its revenue range or aggregate net asset value. The company has also confirmed that the offering is not connected to a business combination transaction. A placement agent's fee was paid, which included a cash fee and ordinary shares of the company. The total number of investors in the offering was one, and no proceeds from the offering are proposed to be used for payments to executive officers, directors, or promoters. The CEO of NeuroSense Therapeutics, Alon Ben-Noon, signed the filing on April 25, 2024.
NeuroSense Therapeutics Ltd., a biotechnology company incorporated in Israel, has successfully completed an exempt offering of securities, raising a total of $4,470,000 USD as reported in a new Form D notice filed with the U.S. Securities and Exchange Commission (SEC). The offering, which included options, warrants, or other rights to acquire securities, was conducted under Rule 506(b) of the Securities Act. The date of the first sale was April 15, 2024, and the company intends the offering to last more than one year. NeuroSense Therapeutics has declined to disclose its revenue range or aggregate net asset value. The company has also confirmed that the offering is not connected to a business combination transaction. A placement agent's fee was paid, which included a cash fee and ordinary shares of the company. The total number of investors in the offering was one, and no proceeds from the offering are proposed to be used for payments to executive officers, directors, or promoters. The CEO of NeuroSense Therapeutics, Alon Ben-Noon, signed the filing on April 25, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.